ConductScience.org, home

Paper31431

Distribution of pellets in the gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets.

Bechgaard H and 1 other. J Pharm Pharmacol, 1978. Cited by 77 papers, by iCite.

Cite this record

ConductScience Library. Distribution of pellets in the gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets. Papers, record 31431. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31431

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Distribution of pellets in the gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets.
PubMed
Journal
J Pharm Pharmacol
PubMed
Year
1978
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
77
iCite
Relative citation ratio, by iCite
4.51
iCite
Revised in PubMed
2019-07-10
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bechgaard HH
2Ladefoged KK

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Digestive SystemMajor topic
Adult
Delayed-Action Preparations
Female
Half-Life
Humans
Ileostomy
Male
Middle Aged
Time Factors

Source PubMed

Download CSV of topics

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.

PMIDTitleJournalYearIn PapersSource
39034723Cutting-Edge Developments and Patent Trends in Microspheres Drug Delivery: A Comprehensive Overview.Recent Pat Nanotechnol2025https://conductscience.org/library/papers/39034723PubMed
35893801Rational Design of Self-Emulsifying Pellet Formulation of Thymol: Technology Development Guided by Molecular-Level Structure Characterization and Ex Vivo Testing.Pharmaceutics2022https://conductscience.org/library/papers/35893801PubMed
26832133Design and optimization of gastro-retentive microballoons for enhanced bioavailability of cinnarizine.Drug Deliv Transl Res2016https://conductscience.org/library/papers/26832133PubMed
26747332A trial for the design and optimization of pH-sensitive microparticles for intestinal delivery of cinnarizine.Drug Deliv Transl Res2016https://conductscience.org/library/papers/26747332PubMed
25383377Development and characterization of novel site specific hollow floating microspheres bearing 5-Fu for stomach targeting.ScientificWorldJournal2014https://conductscience.org/library/papers/25383377PubMed
24967594Characterizations of plasticized polymeric film coatings for preparing multiple-unit floating drug delivery systems (muFDDSs) with controlled-release characteristics.PLoS One2014https://conductscience.org/library/papers/24967594PubMed
24271583The effect of density on the gastric emptying of single- and multiple-unit dosage forms.Pharm Res1986https://conductscience.org/library/papers/24271583PubMed
22615618Preparation and characterization of superporous hydrogels as gastroretentive drug delivery system for rosiglitazone maleate.Daru2010https://conductscience.org/library/papers/22615618PubMed
18459051Preparation of a matrix type multiple-unit gastro retentive floating drug delivery system for captopril based on gas formation technique: in vitro evaluation.AAPS PharmSciTech2008https://conductscience.org/library/papers/18459051PubMed
18181540Formulation and development of floating capsules of celecoxib: in vitro and in vivo evaluation.AAPS PharmSciTech2007https://conductscience.org/library/papers/18181540PubMed
16353995Floating drug delivery systems: a review.AAPS PharmSciTech2005https://conductscience.org/library/papers/16353995PubMed
10325730Gastric emptying and intestinal transit of pancreatic enzyme supplements in cystic fibrosis.Arch Dis Child1999https://conductscience.org/library/papers/10325730PubMed
8234170A floating controlled-release drug delivery system: in vitro-in vivo evaluation.Pharm Res1993https://conductscience.org/library/papers/8234170PubMed
8043223Novel oral drug formulations. Their potential in modulating adverse effects.Drug Saf1994https://conductscience.org/library/papers/8043223PubMed
7859778Radiopharmaceuticals and the gastrointestinal tract.Eur J Nucl Med1994https://conductscience.org/library/papers/7859778PubMed
7075656Bioavailability of indomethacin from two multiple-units controlled-release formulations.Eur J Clin Pharmacol1982https://conductscience.org/library/papers/7075656PubMed
6374610Oral controlled release dosage forms. A review.Pharm Weekbl Sci1984https://conductscience.org/library/papers/6374610PubMed
4007033In vitro--in vivo correlation of dissolution, a time scaling problem? Transformation of in vitro results to the in vivo situation, using theophylline as a practical example.Eur J Clin Pharmacol1985https://conductscience.org/library/papers/4007033PubMed
3525340Where do all the tablets go in 1986?Gut1986https://conductscience.org/library/papers/3525340PubMed
2293216Gastrointestinal transit of nondisintegrating, nonerodible oral dosage forms in pigs.Pharm Res1990https://conductscience.org/library/papers/2293216PubMed

See all 22 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31431

GET https://conductscience.org/api/papers/v1/31431/cited_by?page=2